Politico Europe reports:
The Russian-developed Sputnik V vaccine is 91.6 percent effective in protecting against symptomatic COVID-19 — on par with the currently approved Western jabs, according to a peer-reviewed study published in The Lancet Tuesday.
The data is from a Phase 3 study, with almost 20,000 participants across a number of hospitals and clinics in Russia taking part in the two-dose scheme.
Starting from 21 days after the first dose, there were 16 cases of symptomatic COVID-19 in the vaccine group versus 62 cases in the placebo group, researchers reported. There were no cases of “moderate or severe” coronavirus infections in the vaccinated group 21 days after the first dose.
Read the full article.
BREAKING: Russia’s coronavirus vaccine, Sputnik V, is 91.6 percent effective, according to a peer-reviewed study published today in the medical journal The Lancet.
The data comes from a Phase 3 study of almost 20,000 participants. https://t.co/R3XrbrNmLr
— POLITICOEurope (@POLITICOEurope) February 2, 2021